• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ambrx Biopharma Inc.

    2/27/23 4:05:13 PM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMAM alert in real time by email
    SC 13G 1 tm237743d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )*

      

    Ambrx Biopharma Inc.

    (Name of Issuer)

     

    Ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    02290A102**

    (CUSIP Number)

     

    February 16, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    ** There is no CUSIP number assigned to the ordinary shares. The CUSIP number 02290A102 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the New York Stock Exchange under the symbol “AMAM.” Each ADS represents seven (7) ordinary shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 02290A102   Page 2 of 17

     

    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

     

     

     

     

    CUSIP No. 02290A102   Page 3 of 17

     

    1.

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

     

     

     

     

    CUSIP No. 02290A102   Page 4 of 17

     

    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

      

     

     

     

    CUSIP No. 02290A102   Page 5 of 17

     

    1.  

    Name of reporting persons

     

    VHCP Management III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

     

     

     

     

    CUSIP No. 02290A102   Page 6 of 17

     

    1.  

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

     

     

     

     

    CUSIP No. 02290A102   Page 7 of 17

     

    1.  

    Name of Reporting Persons

     

    Shah, Nimish

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

     

     

     

     

    CUSIP No. 02290A102   Page 8 of 17

     

    1.  

    Name of Reporting Persons

     

    Koh, Bong

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    26,740,0002

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    26,740,0002

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    26,740,0002

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    9.9%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 American Depositary Shares (“ADSs”) held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. Each ADS represents seven (7) ordinary shares.

     

    3  This percentage is calculated based upon 270,328,483 ordinary shares (including in the form of ADSs) outstanding as of June 30, 2022, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022.

     

     

     

     

    CUSIP No. 02290A102   Page 9 of 17

     

    Introductory Note: This Schedule 13G is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the ordinary shares of Ambrx Biopharma Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Ambrx Biopharma Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    10975 Torrey Pines Road

    La Jolla, California 92037

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

      (d) Title of Class of Securities

     

    Ordinary shares, par value $0.0001 per share.

     

      (e) CUSIP Number

     

    02290A102. There is no CUSIP number assigned to the ordinary shares. The CUSIP number 02290A102 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the New York Stock Exchange under the symbol “AMAM.” Each ADS represents seven (7) ordinary shares.

     

     

     

     

    CUSIP No. 02290A102   Page 10 of 17

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of February 27, 2023:

     

    Venrock Healthcare Capital Partners III, L.P.   26,740,000(1)
    VHCP Co-Investment Holdings III, LLC   26,740,000(1)
    Venrock Healthcare Capital Partners EG, L.P.   26,740,000(1)
    VHCP Management III, LLC   26,740,000(1)
    VHCP Management EG, LLC   26,740,000(1)
    Nimish Shah   26,740,000(1)
    Bong Koh   26,740,000(1)

     

      (b) Percent of Class as of February 27, 2023:

     

    Venrock Healthcare Capital Partners III, L.P.   9.9%
    VHCP Co-Investment Holdings III, LLC   9.9%
    Venrock Healthcare Capital Partners EG, L.P.   9.9%
    VHCP Management III, LLC   9.9%
    VHCP Management EG, LLC   9.9%
    Nimish Shah   9.9%
    Bong Koh   9.9%

     

      (c) Number of shares as to which the person has, as of February 27, 2023:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners III, L.P.   26,740,000(1)
    VHCP Co-Investment Holdings III, LLC   26,740,000(1)
    Venrock Healthcare Capital Partners EG, L.P.   26,740,000(1)
    VHCP Management III, LLC   26,740,000(1)
    VHCP Management EG, LLC   26,740,000(1)
    Nimish Shah   26,740,000(1)
    Bong Koh   26,740,000(1)

     

     

     

     

    CUSIP No. 02290A102   Page 11 of 17

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners III, L.P.   26,740,000(1)
    VHCP Co-Investment Holdings III, LLC   26,740,000(1)
    Venrock Healthcare Capital Partners EG, L.P.   26,740,000(1)
    VHCP Management III, LLC   26,740,000(1)
    VHCP Management EG, LLC   26,740,000(1)
    Nimish Shah   26,740,000(1)
    Bong Koh   26,740,000(1)

     

    (1) Consists of (i) 7,029,946 ordinary shares in the form of 1,004,278 ADSs held by Venrock Healthcare Capital Partners III, L.P., (ii) 703,262 ordinary shares in the form of 100,466 ADSs held by VHCP Co-Investment Holdings III, LLC and (iii) 19,006,792 ordinary shares in the form of 2,715,256 ADSs held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

      

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

      

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 02290A102   Page 12 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 27, 2023

     

    Venrock Healthcare Capital Partners III, L.P.  
       
    By: VHCP Management III, LLC  
    Its: General Partner  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    VHCP Management III, LLC  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    Venrock Healthcare Capital Partners EG, L.P.  
       
    By: VHCP Management EG, LLC  
    Its: General Partner  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    VHCP Management EG, LLC  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    Nimish Shah  
       
    /s/ Sherman Souther  
    Sherman Souther, Attorney-in-fact  
       
    Bong Koh  
       
    /s/ Sherman Souther  
    Sherman Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 02290A102   Page 13 of 17

     

    EXHIBITS

     

    A:Joint Filing Agreement

     

    B:Power of Attorney for Nimish Shah

     

    C:Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. 02290A102   Page 14 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares of Ambrx Biopharma Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 27th day of February, 2023.

     

    Venrock Healthcare Capital Partners III, L.P.  
       
    By: VHCP Management III, LLC  
    Its: General Partner  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    VHCP Management III, LLC  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    Venrock Healthcare Capital Partners EG, L.P.  
       
    By: VHCP Management EG, LLC  
    Its: General Partner  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  
       
    VHCP Management EG, LLC  
       
    By: /s/ Sherman Souther  
      Name: Sherman Souther  
      Its: Authorized Signatory  

     

     

     

     

    CUSIP No. 02290A102   Page 15 of 17

     

    Nimish Shah  
       
    /s/ Sherman Souther  
    Sherman Souther, Attorney-in-fact  
       
    Bong Koh  
       
    /s/ Sherman Souther  
    Sherman Souther, Attorney-in-fact   

     

     

     

     

    CUSIP No. 02290A102   Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

      (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

      (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 27th day of February, 2023.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. 02290A102   Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

      (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

      (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 27th day of February, 2023.

     

    /s/ Bong Koh  

     

     

     

    Get the next $AMAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAM

    DatePrice TargetRatingAnalyst
    9/25/2023$15.00Mkt Outperform
    JMP Securities
    9/12/2023$26.00Buy
    BTIG Research
    7/31/2023$29.00Outperform
    RBC Capital Mkts
    6/14/2023$26.00Buy
    B. Riley Securities
    6/2/2023$30.00Outperform
    Oppenheimer
    5/19/2023$25.00Overweight
    Cantor Fitzgerald
    4/7/2022$16.00Outperform
    Robert W. Baird
    2/28/2022$6.00Neutral
    Goldman Sachs
    More analyst ratings

    $AMAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs

      SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company's global regulatory strategy and will report to the Company's President and Chief Executive Officer, Daniel J. O'Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Phar

      8/1/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Jared Kelly as General Counsel

      SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units. Mr. Kelly is an experienced public company lawyer who

      6/5/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Shareholders Approve Acquisition by Johnson & Johnson

      SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t

      3/6/24 1:20:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Announces Sale to Johnson & Johnson

      SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther

      1/8/24 7:35:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Financials

    Live finance-specific insights

    See more
    • Ambrx to Commence Trading on Nasdaq

      Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM". "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company and is an important step that will help facilitate our mission to di

      3/6/23 9:00:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

      - Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx to host a conference call today at 5:00 p.m. EST / 2:00 p.m. PST - SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company's cash runway, pipeline near term v

      10/18/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma to Host Corporate Update Conference Call

      SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company's strategic review of its development pipeline. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.ambrx.com. To access the call by phone, please use the reg

      10/11/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ambrx Biopharma Inc. (Amendment)

      SC 13G/A - Ambrx Biopharma Cayman, Inc. (0001836056) (Subject)

      2/9/24 5:08:30 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      10/10/23 11:35:22 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      9/25/23 5:24:50 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Ambrx Biopharma with a new price target

      JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00

      9/25/23 7:12:57 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Ambrx Biopharma with a new price target

      BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00

      9/12/23 7:13:06 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

      RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00

      7/31/23 7:17:15 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

      4 - Ambrx Biopharma Inc. (0001836056) (Issuer)

      9/19/23 4:49:06 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ambrx Biopharma Inc.

      15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/18/24 2:45:48 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/12/24 4:55:02 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Ambrx Biopharma Inc.

      EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/11/24 12:15:20 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hermans Kate

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:23:35 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Loesberg Janet

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:19:43 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • O'Connor Daniel J. returned 48,202 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 5:46:49 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care